Get started

Bullishharmonic

#Dishtv - Bullish Harmonic - Anti shark Pattern observed#Dishtv - Bullish Harmonic - Anti shark Pattern observed Entry CMP - 12.5 SL on closing basis 10.9 Tgt 1 14.5, tgt 2 16.5 Disclosure : I am not SEBI registered.The information provided here is for education purposes only.I will not be responsible for any of your profit/loss with this channel suggestions.Consult your financial advisor before taking any decisions.Tweets neither advice nor endorsement. Neither the information, nor any opinion contained in this page constitutes a solicitation or offer by the Group to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
NSE:DISHTVLong
by iamkaarthik
GBPZAR - Gartley Harmonic I dont believe in Bearish or Bullish Gartleys. Gartleys are interesting. My thought pattern. X to A pullback 0.618. 0.618 the "perfect" low before a swing up. Fib A to B near enough 0.786 and according to Gartley 0.888 high. Coincidentally has confluence with drawn TOP of ascending channel that can also be known as a "possible" and "probable" resistance. The pullback again Gartley level, would be an approximate to the decending channel (red) at 0.782. Interesting. : ) Be looking at a possible reversal at 0.382 approx 20.5 to break the pattern on the downtrend.
by hmaroudas
Scenario 2 (Bullish Shark) 19.5k OR 18.3kBullish Shark pattern target is matching the numbers - it says 19.5k for the 0.886 fib, or 18.3k for the 1.618 fib. Either one can happen. The 1.113 fib has confirmed our top for BTC at X-B (it head dead on) I have changed my LONG to order at 18.3k, with the same LONG TP as in the "Link to Related Ideas" chart I posted yesturday. The thing that convinces me is the 1.113 of OX is the exact same point as the 1.618 of AB, that is 18.3k. Therefore, I am leaning more towards 18.3k. 18.3k would also make a lot of Bears think its going much lower (bear flag fakeout). ----------------- Bullish Shark rules: The Shark pattern has the following ratios. CONFIRMED - AB leg extends OX leg between 113% – 161.8% (because of this, 26.5k is also kind of possible but not likely now, whales just pushed price up to form this harmonic and then BARTed it.) CONFIRMED - BC leg extends beyond O by 113% of the OX leg LETS SEE - BC leg is also an extension of AX by 161.8% – 224% Unlike other harmonic patterns, the trades are entered as follows: Entry is at 88.6% of OX leg (19.5k) with stops coming in below point C (18.3k or 19.5k, so lets say 18.1k) Targets can be 61.8% of BC (This would be around 22,222 if 1.618 reaches and 22.7k if only the 0.886 reaches)
COINBASE:BTCUSD
by reiiss7
4
$PTPI SYMMETRICAL TRIANGLE$PTPI: SI 25% |BC 150% SYMMETRICAL TRIANGLE Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease; and markets its own line of ED products in the form of vacuum erection device products. The company is based in New York, New York.
NASDAQ:PTPILong
by BADQOMOCAWGOWLD
$SOPA entry PTs 9.65-12 Target PTs 22-27 and higherOn Sunday, Society Pass announced that its stock was being added to the Russell 2000 Index, effective at the open of the U.S. markets on Monday, Dec. 20. This index comprises 2,000 U.S.-listed small-cap stocks (stocks with market caps of $300 million to $2 billion). Stocks almost always get a big boost following news that they'll be added to a major index because this means that index-based funds will have to buy them. Moreover, this type of news also increases a company's exposure to the investing community. As more investors become aware of the existence of a publicly traded company, some of them will probably decide to buy its shares. According to the company's website, it's "building the next generation loyalty and data-focused marketing platform in Southeast Asia and South Asia. .... As more merchants and consumers in SEA and South Asia register on our Society Pass platform, more transaction data is generated. With more data generation, there are more opportunities for creating loyalty from consumers to merchants." Society Pass Incorporated engages in the acquisition and operation of e-commerce platforms for consumers and merchants in Southeast Asia. The company's e-commerce interfaces include consumer facing segment comprising SoPa food & beverage App, SoPa.asia F&B Marketplace website, Leflair App, and Leflair Lifetyle Marketplace website; and merchant facing segment, such as #HOTTAB Biz App, #HOTTAB POS App, and Hottab.net admin website. Its loyalty-focused e-commerce marketing platform interfaces connect consumers with merchants in the F&B and lifestyle sectors. The company was formerly known as Food Society, Inc. and changed its name to Society Pass Incorporated in October 2018. Society Pass Incorporated was incorporated in 2018 and is based in Carson City, Nevada.
NASDAQ:SOPA
by BADQOMOCAWGOWLD
$CPIXCumberland Pharmaceuticals shares are trading higher after the company announced the FDA approved expanded labeling for Caldolor to now include use in pre-operative administration. Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
NASDAQ:CPIXLong
by BADQOMOCAWGOWLD